Mumbai-based Transasia Bio-Medicals, one of India’s leading players in the in-vitro diagnostics sector, is evaluating a strategic plan to raise between $150 million and $200 million. As part of this initiative, the medical equipment manufacturer is exploring the sale of up to a 20% stake in the company. If completed, this would mark the company’s first significant venture into raising external capital.
According to individuals familiar with the matter, the potential fundraise has already attracted interest from several prominent private equity firms. Among those reported to have expressed interest are TPG, Warburg Pincus, ChrysCapital, Motilal Oswal, and Quadria Capital. While these discussions remain in the preliminary stages, sources indicate that the final deal structure—likely a combination of primary and secondary share sales—may evolve based on the requirements of the incoming investor. O3 Capital is currently serving as the financial advisor assisting Transasia with the transaction.
Founded in 1979 by Suresh Vazirani, Transasia was established to mitigate India’s historical dependence on imported medical equipment, which was often hindered by frequent maintenance issues and a lack of robust after-sales infrastructure. Over the decades, the company transformed from an importer-distributor into a major manufacturer. Today, it operates as a key entity within the Erba group, maintaining a global presence across 150 countries. Its manufacturing footprint includes five factories distributed across India, the Czech Republic, and Russia, supported by three dedicated research and development centers. The company is currently under the leadership of Global CEO Nishant Saxena, a former executive at Cipla.
The company maintains a broad product portfolio covering biochemistry, hematology, coagulation, immunology, urinalysis, critical care, and molecular diagnostics. In the domestic market, Transasia faces competition from a mix of established local and international diagnostic device manufacturers, including names such as Tulip Diagnostics, Accurex Biomedical Pvt. Ltd, Trivitron Healthcare, and Roche Diagnostics.
This move to secure private equity funding comes against the backdrop of a rapidly expanding Indian medical technology landscape. Data from an EY report highlights that India’s medtech market reached a valuation of $12 billion in fiscal year 2024 and is projected to scale to $50 billion by 2030. Within this ecosystem, in-vitro diagnostics accounts for approximately 8.1% of the market, which is dominated by electronic equipment at 56%. Industry analysts expect India’s contribution to the global market to climb significantly over the next quarter-century, rising from its current 1.65% share to an estimated 10% to 12%.
Several macroeconomic and structural factors are fueling this growth. Increased disposable incomes, the rapid expansion of health insurance penetration, and the flourishing medical tourism industry are driving parallel demand for both high-end innovative devices and cost-effective medical solutions. Furthermore, improved healthcare infrastructure in Tier 2 and Tier 3 cities has unlocked vast new consumer bases, prompting companies like Transasia to strengthen their balance sheets to capitalize on these emerging opportunities.

